| Atypical HUS |
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry |
Open to enrollment |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 |
|
| Bleeding and clotting disorders |
CDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders |
Open |
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996 |
|
| Blood clots in cancer patients |
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effects of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ANT-007) |
Open to enrollment
 |
PI: Kristen Sanfilippo
Contact: Kim Kramer
kramerka@wustl.edu
314-273-1790 |
|
| Blood clots in cancer patients |
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI) / genitourinary (GU) cancer associated VTE (ANT-008) |
Open to enrollment
|
PI: Kristen Sanfilippo
Contact: Kim Kramer
kramerka@wustl.edu
314-273-1790 |
|
| Essential Thrombocythemia |
A Phase 3 Study of P1101 vs Anagrelide in Essential Thrombocythemia Patients who Failed Hydroxyurea (P1101ET) |
Open to enrollment
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Essential Thrombocythemia |
A Phase 2b Open Label Study of Ropeginterferon (P1101) in Essential Thrombocythemia Patients |
Pending Open
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Hemophilia A |
A Phase 3 Study of Valoctocogene Roxaparvovec in Hemophilia A Patients |
Open |
PI: Elaine Majerus
Contact: Rachel Cody
rcody@wustl.edu
314-362-7306 |
|
| Hemophilia A |
Emicizumab In Patients With Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial |
Enrollment pending
|
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 |
|
| Hemophilia A |
Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors |
Open to enrollment
|
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 |
|
| Hemophilia/Bleeding |
American Thrombosis and Hemostasis Network Data Collection |
Open |
PI: Elaine Majerus
Contact: Bill Berger
bergerwb@wustl.edu
314-362-9996 |
|
| Myelofibrosis |
Extended Access of Momelotinib in Adults with Myelofibrosis (352-4365) |
Enrolling by invitation only
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Myelofibrosis |
A Phase 2 Dose Expansion Study of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis (MANIFEST) |
Ongoing; closed to enrollment
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Myelofibrosis |
Phase 2 Study of KRT-232 in Myelofibrosis Patients Who Failed Prior JAK Inhibitor |
Open to enrollment
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Myelofibrosis |
A Phase 1/2 study of INCB000928 ± Ruxolitinib in Myelofibrosis Patients with Anemia (INCB 00928-104) |
Open to enrollment
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Myelofibrosis |
A Phase 3 Study of Pelabresib (CPI-0610) plus Ruxolitinib vs Placebo plus Ruxolitinib in Myelofibrosis Patients |
Ongoing; closed to enrollment
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Myelofibrosis |
A Phase 1b/2a Study of DISC-0974 in Myelofibrosis Patients with Anemia (DISC-0974-102) |
Pending Open
|
PI: Amy Zhou
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| PNH |
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry |
Open to enrollment |
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 |
|
| PNH |
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan |
Pending enrollment
|
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 |
|
| Polycythemia Vera |
A Phase 2a Study of ISIS 702843 in Phlebotomy Dependent Polycythemia Vera Patients (ISIS 702843-CS4) |
Open to enrollment
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Polycythemia Vera |
A Phase 3b Study of Ropeginterferon (P1101) in Polycythemia Vera Patients |
Pending Open
|
PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156 |
|
| Sickle Cell Disease |
Patient Characteristics and Treatment Patterns from Early Crizanlizumab Use in Real-world Setting |
|
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998 |
|
| Sickle Cell Disease |
Sickle Cell Disease Patient Registry (SCDIC-II) |
Enrolling
|
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051 |
|
| Sickle Cell Disease |
The Epidemiology of Silent and Overt Strokes in Adults with Sickle Cell Disease |
Enrolling
|
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051 |
|
| Sickle Cell Disease |
Globin research Network for DATA and Discovery (GRNDaD) |
|
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998 |
|
| Sickle Cell Disease |
Globin research Network for DATA and Discovery (GRNDaD) substudy - HUGS |
|
PI: Sana Saif Ur Rehman
Contact: Isuru Gamlath
isuru.gamlath@wustl.edu
314-362-9998 |
|
| Sickle Cell Disease |
Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange Trial (SCD-CARRE) |
Enrolling
|
PI: Allison King
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-0051 |
|
| Systemic Mastocytosis |
A Phase 2 Study of CGT9486 in Patients with Nonadvanced Systemic Mastocytosis (Summit) |
Open to enrollment
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Systemic Mastocytosis |
A Phase 2 Study of Avapritinib (BLU-285) in Nonadvanced Systemic Mastocytosis Patients with Inadequately Controlled Symptoms (BLU-285-2203) |
Ongoing; closed to enrollment
|
PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960 |
|
| Von Willebrand Disease |
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD) |
Open to enrollment
|
PI: Elaine Majerus
Contact: Sabrina Barber
s.barber@wustl.edu
314-273-1440 |
|
